Quick Answer
Anixa Biosciences Inc reported Operating Income Loss of -$11.70 million for the year ending 2025.
- Anixa Biosciences Inc showed an increase of +15.4% in Operating Income Loss from 2024 to 2025.
- This data is from Anixa Biosciences Inc's annual report (Form 10-K), filed with the SEC on January 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Anixa Biosciences Inc's Operating Income Loss has declined by 123.0%.
- Historical annual values: Fiscal year 2025: -$11.70 million | Fiscal year 2024: -$13.83 million | Fiscal year 2023: -$11.01 million | Fiscal year 2022: -$13.88 million | Fiscal year 2021: -$13.14 million | Fiscal year 2020: -$9.98 million | Fiscal year 2019: -$11.89 million | Fiscal year 2018: -$14.29 million | Fiscal year 2017: -$6.08 million | Fiscal year 2016: -$4.51 million | Fiscal year 2015: -$944.8 thousand | Fiscal year 2014: -$5.04 million | Fiscal year 2013: -$7.92 million | Fiscal year 2012: -$4.13 million | Fiscal year 2011: -$5.03 million | Fiscal year 2010: -$5.25 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: